IDEXX LaboratoriesFRA:IX1 -0.19%96 ROE % is 70.92% as of Mar. 2026, which is 32% below its 10-year median of 104.58. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €544.17 (Modestly Undervalued). Among 203 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 95.07% on this metric.
The historical rank and industry rank for IDEXX Laboratories's ROE % or its related term are showing as below:
FRA:IX1'
s ROE % Range Over the Past 10 Years
Min: 57.66 Med: 104.58 Max: 509.31
Current: 71.78
During the past 13 years, IDEXX Laboratories's highest ROE % was 509.31%. The lowest was 57.66%. And the median was 104.58%.
FRA:IX1's ROE % is ranked better than 95.07% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.22
vs FRA:IX1: 71.78
IDEXX Laboratories (FRA:IX1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
IDEXX Laboratories ROE % Related Terms
IDEXX Laboratories ROE % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's ROE % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
IDEXX Laboratories (FRA:IX1) has a ROE % of 70.92% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on IDEXX Laboratories and its competitors. This is 32% below median its historical median of 104.58. Over the past decade, IDEXX Laboratories' ROE % has ranged from 57.66 to 509.31. According to the industry distribution chart, IDEXX Laboratories ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 4.9%.
Is IDEXX Laboratories' ROE % too high?
IDEXX Laboratories' current ROE % of 70.92% is 32% below median its 10-year median of 104.58. Over the past 10 years, this metric has ranged from a low of 57.66 to a high of 509.31. Based on the distribution chart, IDEXX Laboratories ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' ROE % compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #10 out of 203 companies for ROE %. This places IDEXX Laboratories in the top 5% of its industry — outperforming the majority of peers. Historically, IDEXX Laboratories' own ROE % has ranged from 57.66 to 509.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current ROE % is 70.92%, which is 32% below median its own 10-year median of 104.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €544.17, compared to a current price of €473.80 — trading 12.9% below its estimated fair value. The current ROE % is 70.92%, which is 32% below median its 10-year median of 104.58. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current ROE % is 70.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 12.9% below its estimated GF Value™ of €544.17.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
ROE %: 70.92% (32% below median its 10-year median of 104.58)
GF Value™: €544.17 vs. price of €473.80 (12.9% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
